Amanda Feilding will be among the speakers taking part in a very special panel discussion highlighting how the latest research on psychedelics is shattering the stigma around these extraordinary materials and bringing them into the fold of contemporary medicine. A Psychedelic Conversation: Tackling The Taboo will take place on Tuesday, February 21st, at Cambridge University’s Physiological Laboratory Lecture Theatre, and will be hosted by CamBrain: The Cambridge Neuroscience Society.
While the outlawing of psychedelic drugs like LSD, psilocybin and DMT has seen them banished from the mainstream scientific agenda for over half a century, depriving an entire generation of their therapeutic benefits, a new tide is now rising within the global neuroscientific community. Amanda and the Beckley Foundation are very much at the forefront of this psychedelic renaissance, having conducted studies that reveal how the brain alterations brought about by LSD loosen the grip of the brain’s most repressive networks, allowing users to break free from rigid modes of thought and behaviour, such as those that underlie addiction and depression. We have also shown how compounds in ayahuasca stimulate the birth of new brain cells, and that psilocybin can effectively alleviate depression in sufferers who have failed to respond to other treatments.
Amanda will be talking about how these findings are forcing the gatekeepers of the mainstream scientific world to take notice, and will be joined by the likes of Leor Roseman, whose work in the Beckley/Imperial Research Programme has helped to reveal how LSD produces visual hallucinations in the brain.
Psilocybin for Depression
Type of publication